Higher Development Costs and Longer Timelines Due to Stricter Pesticide Registration Requirements
First written in FY2016. 5 of 7 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Restated".
- FY2026RestatedAnnual report
「The business environment is becoming increasingly challenging due to the increasing difficulty of drug discovery, the growing number of pesticide registration requirements, price competition from generic pesticides, heightened geopolitical risks, and higher production and procurement costs resulting from soaring raw material and energy prices.」
The company continues to explain the burden of higher development costs and longer timelines resulting from the increasing difficulty of drug discovery and additional registration requirements, along with price competition, geopolitical risks, and soaring raw material and energy prices. - FY2025RestatedAnnual report
「In addition, the increasing difficulty of drug discovery and the growing number of pesticide registration requirements have driven up the cost of developing new products and extended development timelines. Requirements under pesticide registration systems in various countries have also become more stringent.」
The company continues to explain that development costs and timelines are increasing due to the growing difficulty of drug discovery, additional registration requirements and tighter regulations in various countries. - FY2023RestatedAnnual report
「In addition, the increasing difficulty of drug discovery and the growing number of pesticide registration requirements have driven up the cost of developing new products and extended development timelines. Requirements under pesticide registration systems in various countries have also become more stringent.」
The company continues to explain that development costs and timelines are increasing due to the growing difficulty of drug discovery, additional registration requirements and tighter regulations in various countries. - FY2018RestatedAnnual report
「In addition, as drug discovery becomes more difficult and pesticide registration requirements increase, the cost of developing new products is rising and development periods are becoming longer. The business environment surrounding the Group is also becoming increasingly challenging due to stricter requirements under pesticide registration systems in various countries, price competition with generic pesticides, and higher raw material and contract manufacturing costs.」
The company reconfirmed the risk of higher development costs and longer development periods due to greater difficulty in drug discovery and increased and stricter registration requirements. - FY2018-Q4WorsenedAnnual report
「In overseas pesticide markets, regulatory tightening is under way in Europe, while demand trends varied by region: Brazil, the largest market, contracted, whereas North America and Asia remained steady.」
The company specifically described moves toward tighter regulation in Europe regarding pesticide registration and regulatory requirements. - FY2017RestatedAnnual report
「As drug discovery becomes more difficult and pesticide registration requirements increase, the cost of developing new products is rising and development periods are becoming longer. In addition, the business environment surrounding the Group is becoming increasingly challenging due to stricter requirements under pesticide registration systems in various countries, price competition with generic pesticides, and higher raw material and contract manufacturing costs.」
The company reconfirmed the risk of higher and longer-term development costs due to greater difficulty in drug discovery and stricter registration requirements. - FY2016First statedAnnual report
「As drug discovery becomes more difficult and pesticide registration requirements increase, the cost of developing new products is rising and development periods are becoming longer. In addition, increasingly stringent requirements under pesticide registration systems in various countries are making the business environment surrounding the Group even more challenging.」
The company indicated the risk of higher development costs and longer development periods due to greater difficulty in drug discovery and increased and stricter registration requirements.